Literature DB >> 6198888

Analysis of neurotransmitter metabolites and adenosine 3',5'-monophosphate in the CSF of patients with extrapyramidal motor disorders.

H Cramer, J M Warter, B Renaud.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6198888

Source DB:  PubMed          Journal:  Adv Neurol        ISSN： 0091-3952


× No keyword cloud information.
  14 in total

1.  Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington's disease.

Authors:  Motomasa Tanaka; Koko Ishizuka; Yoko Nekooki-Machida; Ryo Endo; Noriko Takashima; Hideyuki Sasaki; Yusuke Komi; Amy Gathercole; Elaine Huston; Kazuhiro Ishii; Kelvin Kai-Wan Hui; Masaru Kurosawa; Sun-Hong Kim; Nobuyuki Nukina; Eiki Takimoto; Miles D Houslay; Akira Sawa
Journal:  J Clin Invest       Date:  2017-03-06       Impact factor: 14.808

2.  Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington's disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway.

Authors:  Priyanka Saroj; Yashika Bansal; Raghunath Singh; Ansab Akhtar; Rupinder Kaur Sodhi; Mahendra Bishnoi; Sangeeta Pilkhwal Sah; Anurag Kuhad
Journal:  Inflammopharmacology       Date:  2021-01-31       Impact factor: 4.473

3.  Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.

Authors:  Fernando E Padovan-Neto; Stephen Sammut; Shreaya Chakroborty; Alexander M Dec; Sarah Threlfell; Peter W Campbell; Vishnu Mudrakola; John F Harms; Christopher J Schmidt; Anthony R West
Journal:  J Neurosci       Date:  2015-04-08       Impact factor: 6.167

Review 4.  Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington's disease.

Authors:  Antonella Cardinale; Francesca R Fusco
Journal:  CNS Neurosci Ther       Date:  2018-03-03       Impact factor: 5.243

5.  Ventricular somatostatin-like immunoreactivity in patients with basal ganglia disease.

Authors:  H Cramer; A Wolf; K Rissler; K Weigel; C Ostertag
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

6.  Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.

Authors:  Carmela Giampà; Daunia Laurenti; Serenella Anzilotti; Giorgio Bernardi; Frank S Menniti; Francesca Romana Fusco
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

7.  Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition.

Authors:  Sarah Threlfell; Anthony R West
Journal:  Basal Ganglia       Date:  2013-12-01

Review 8.  The energetics of Huntington's disease.

Authors:  Susan E Browne; M Flint Beal
Journal:  Neurochem Res       Date:  2004-03       Impact factor: 3.996

9.  CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  Patrick Oeckl; Petra Steinacker; Stefan Lehnert; Sarah Jesse; Hans A Kretzschmar; Albert C Ludolph; Markus Otto; Boris Ferger
Journal:  PLoS One       Date:  2012-03-02       Impact factor: 3.240

Review 10.  Plants and phytochemicals for Huntington's disease.

Authors:  Sunayna Choudhary; Puneet Kumar; Jai Malik
Journal:  Pharmacogn Rev       Date:  2013-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.